Literature DB >> 19582559

Studying the interaction of pirarubicin with DNA and determining pirarubicin in human urine samples: combining excitation-emission fluorescence matrices with second-order calibration methods.

Hong-Yan Zou1, Hai-Long Wu, Yan Zhang, Shu-Fang Li, Jin-Fang Nie, Hai-Yan Fu, Ru-Qin Yu.   

Abstract

In this paper, UV-vis spectroscopy and fluorescence were combined to study the binding of Calf thymus DNA (ct-DNA) with the anthacycline antibiotic drug pirarubicin (THP). Ethidium bromide (EB) as the fluorescence probe was used to study the competitive binding interactions of THP with DNA by excitation-emission fluorescence matrices (EEFMs) coupled with the parallel factor analysis (PARAFAC) and the alternating normalization-weighted error algorithm (ANWE) with the second-order advantage. All the results conformed that THP mainly bound with DNA by intercalation. Meanwhile, the two second-order calibration methods have been successfully applied to quantify THP in urine samples. Figures of merit were applied to compare the performance of the two methods. The results presented in this work showed that both the PARAFAC and ANWE methods were the convincing way to be applied in the complex biological systems even in the presence of uncalibrated interferences.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19582559     DOI: 10.1007/s10895-009-0495-6

Source DB:  PubMed          Journal:  J Fluoresc        ISSN: 1053-0509            Impact factor:   2.217


  34 in total

1.  Influence of substituent modifications on DNA binding energetics of acridine-based anticancer agents.

Authors:  Rachel A Hutchins; James M Crenshaw; David E Graves; William A Denny
Journal:  Biochemistry       Date:  2003-11-25       Impact factor: 3.162

2.  New acridone derivatives for the electrochemical DNA-hybridisation labelling.

Authors:  B Wang; L Bouffier; M Demeunynck; P Mailley; A Roget; T Livache; P Dumy
Journal:  Bioelectrochemistry       Date:  2004-06       Impact factor: 5.373

3.  Thermochemistry of protein-DNA interaction studied with temperature-controlled nonequilibrium capillary electrophoresis of equilibrium mixtures.

Authors:  Maxim Berezovski; Sergey N Krylov
Journal:  Anal Chem       Date:  2005-03-01       Impact factor: 6.986

4.  Intra-laboratory testing of method accuracy from recovery assays.

Authors:  A G González; M A Herrador; A G Asuero
Journal:  Talanta       Date:  1999-03       Impact factor: 6.057

5.  Theoretical aspects of DNA-protein interactions: co-operative and non-co-operative binding of large ligands to a one-dimensional homogeneous lattice.

Authors:  J D McGhee; P H von Hippel
Journal:  J Mol Biol       Date:  1974-06-25       Impact factor: 5.469

6.  Solute perturbation of protein fluorescence. The quenching of the tryptophyl fluorescence of model compounds and of lysozyme by iodide ion.

Authors:  S S Lehrer
Journal:  Biochemistry       Date:  1971-08-17       Impact factor: 3.162

7.  Investigation of quadruplex oligonucleotide-drug interactions by electrospray ionization mass spectrometry.

Authors:  Wendi M David; Jennifer Brodbelt; Sean M Kerwin; Pei Wang Thomas
Journal:  Anal Chem       Date:  2002-05-01       Impact factor: 6.986

8.  Enzymatic activation of a new antitumour drug, 5-diethylaminoethylamino-8-hydroxyimidazoacridinone, C-1311, observed after its intercalation into DNA.

Authors:  Z Mazerska; J Dziegielewski; J Konopa
Journal:  Biochem Pharmacol       Date:  2001-03-15       Impact factor: 5.858

9.  Electrochemical study of quercetin-DNA interactions: part II. In situ sensing with DNA biosensors.

Authors:  Ana Maria Oliveira-Brett; Victor C Diculescu
Journal:  Bioelectrochemistry       Date:  2004-09       Impact factor: 5.373

10.  Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II.

Authors:  K M Tewey; T C Rowe; L Yang; B D Halligan; L F Liu
Journal:  Science       Date:  1984-10-26       Impact factor: 47.728

View more
  7 in total

1.  Pirarubicin-based chemotherapy displayed better clinical outcomes and lower toxicity than did doxorubicin-based chemotherapy in the treatment of non-metastatic extremity osteosarcoma.

Authors:  Shuier Zheng; Shuhui Zhou; Guanglei Qiao; Qingcheng Yang; Zhichang Zhang; Feng Lin; Daliu Min; Lina Tang; Hongtao Li; Yuanjue Sun; Hui Zhao; Zan Shen; Yang Yao
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

2.  Evaluation of pirarubicin-cisplatin chemotherapy in the treatment for refractory and recurrent high-grade osteosarcoma: experience of a single institute.

Authors:  Wei-Xiang Qi; Ai-Na He; Li-Na Tang; Zan Shen; Yang Yao
Journal:  Med Oncol       Date:  2011-07-07       Impact factor: 3.064

3.  Targeting the MIR34C-5p-ATG4B-autophagy axis enhances the sensitivity of cervical cancer cells to pirarubicin.

Authors:  Yaran Wu; Zhenhong Ni; Xiaojing Yan; Xufang Dai; Changjiang Hu; Yingru Zheng; Fengtian He; Jiqin Lian
Journal:  Autophagy       Date:  2016-04-20       Impact factor: 16.016

4.  Interaction mechanism of Trp-Arg dipeptide with calf thymus DNA.

Authors:  Jing Lin; Canzhu Gao; Rutao Liu
Journal:  J Fluoresc       Date:  2013-04-20       Impact factor: 2.217

5.  Pirarubicin inhibits multidrug-resistant osteosarcoma cell proliferation through induction of G2/M phase cell cycle arrest.

Authors:  Shui-er Zheng; Sang Xiong; Feng Lin; Guang-lei Qiao; Tao Feng; Zan Shen; Da-liu Min; Chun-ling Zhang; Yang Yao
Journal:  Acta Pharmacol Sin       Date:  2012-05-14       Impact factor: 6.150

6.  Interaction of indomethacin with calf thymus DNA: a multi-spectroscopic, thermodynamic and molecular modelling approach.

Authors:  Mohammed Amir Husain; Hassan Mubarak Ishqi; Tarique Sarwar; Sayeed Ur Rehman; Mohammad Tabish
Journal:  Medchemcomm       Date:  2017-04-27       Impact factor: 3.597

7.  Dichloroacetate enhances the antitumor effect of pirarubicin via regulating the ROS-JNK signaling pathway in liver cancer cells.

Authors:  Xiao-Jing Yan; Peng Xie; Xu-Fang Dai; Ling-Xi Chen; Liang-Bo Sun; Tao Li; Wen-Hui He; Zhi-Zhen Xu; Gang Huang; Feng-Tian He; Ji-Qin Lian
Journal:  Cancer Drug Resist       Date:  2020-09-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.